secwatch.observer — SEC 8-K summary
======================================

Issuer:     Gain Therapeutics, Inc. (GANX)
CIK:        0001819411
Form:       8-K
Filed at:   2024-01-31T23:59:59+00:00
Accession:  0001104659-24-008894
Event type: other_material
Sentiment:  positive
Materiality: 0.65
Item codes: 7.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Gain Therapeutics CEO provides operational update; Phase 1 trial advancing, cash runway into 2025
--------------------------------------------------------------------------------

- Phase 1 SAD/MAD trial of GT-02287 underway; MAD cohort expected to start Q1 2024, completion by mid-2024.
- $10.1M gross proceeds from Nov 2023 CMPO/PIPE financing; cash runway into 2025 to fund biomarker proof-of-concept.
- Computational platform renamed Magellan, now integrates AI/ML and screens 50B+ chemical compounds.
- CTO Dr. Xavi Barril leaving; company searching for Chief Medical Officer for clinical development.
- Anticipated milestones: MAD completion, Parkinson's patient cohort Q3 2024, biomarker data late 2024/early 2025.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1819411/000110465924008894/0001104659-24-008894-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1819411/000110465924008894/tm244785d1_8k.htm
  HTML page:      https://secwatch.observer/filing/0001104659-24-008894

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer